BG Medicine, Inc. is a life sciences company, which engages in the provision of developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders. The company is headquartered in Waltham, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2011-02-04. The firm is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The firm's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The firm's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Follow-Up Questions
Quel est le ratio P/E de BG Medicine Inc (BGMD) ?
Le ratio P/E de BG Medicine Inc est de 0
Qui est le CEO de BG Medicine Inc ?
Dr. Paul Sohmer est le President de BG Medicine Inc, il a rejoint l'entreprise depuis 2013.
Quelle est la performance du prix de l'action BGMD ?
Le prix actuel de BGMD est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de BG Medicine Inc ?
BG Medicine Inc appartient à l'industrie Life Sciences Tools & Services et le secteur est Health Care
Quel est la capitalisation boursière de BG Medicine Inc ?
La capitalisation boursière actuelle de BG Medicine Inc est de $11.37
